Testosterone
Pharmacology detail: animal ratings
These ratios are not measured human benefit or safety rankings.
Testosterone is an androgen. Medical replacement and performance use have different goals and risks.
Technical catalog description
Testosterone is the foundation of virtually all anabolic steroid cycles and serves as the gold standard by which all other anabolic steroids are measured.
Read next
Mechanism details
Testosterone works through three pathways simultaneously. It activates androgen receptors directly. It aromatizes to estradiol, which is required for bone density, cardiovascular health, joint lubrication, mood stability, and sexual function. It converts via 5AR to DHT, which drives androgenic effects at hair, skin, and prostate tissue. Managing the balance between these pathways is the actual skill in using testosterone effectively, not just keeping estrogen “in range.”
The aromatization rate is roughly 0.2–0.3% of circulating testosterone per day, concentrated in adipose tissue. This is not fixed. This catalog does not provide a validated prediction of estradiol from an entered amount.
Estrogen is not the enemy. Estradiol amplifies muscle protein synthesis, supports bone density, improves insulin sensitivity, contributes to cardiovascular protection, and is the primary driver of libido and mood in men on cycle. Users who suppress estradiol aggressively in pursuit of a “dry” look typically feel worse, recover worse, and often find joint pain worsening as synovial fluid depends partly on estrogen signaling. The target is not zero estrogen. It is a stable, mid-range estradiol that balances the beneficial effects against water retention and breast tissue sensitivity.
Hematocrit rises on testosterone via erythropoietin stimulation. This profile does not establish a dose-to-hematocrit prediction or a blood-donation schedule for managing exposure.
Ester selection: Esters change the kinetic profile, but the ester name alone does not establish injection frequency. This catalog does not validate an ester-specific regimen.
Loading doses: No loading-dose protocol or dose-to-onset prediction is validated here.
Dose references:
This profile does not establish a weekly amount with “modest” side effects or a minimum effective cycle amount. Product, indication, formulation, and route are needed before using a clinical reference.
These ranges assume lean, healthy baseline. Higher body fat, older age, or pre-existing elevated hematocrit all shift the risk picture upward.
Natural suppression with reduced fertility and testicular output
High estradiol, water retention, and gynecomastia risk if estrogen is unmanaged
CBC / hematocrit
blood pressure
lipid panel
estradiol
Uncontrolled hypertension or untreated cardiovascular disease
Pre-existing severe infertility concerns unless that risk is accepted and managed
Current uncontrolled estrogen-sensitive issues such as active gynecomastia
Testosterone is the starting compound for every cycle because it is the only anabolic drug whose side effect set is fully transparent and well-understood. Estrogen rises; you see it in water retention and blood pressure. Hematocrit climbs; it appears on a CBC. Libido is the best real-time gauge of whether the hormone picture is balanced. Adding more exotic compounds before mastering testosterone means attributing outcomes to the wrong variable every time something goes wrong.
User reports of gains do not establish a reference amount or predict retained tissue growth for an individual.
Unverified community-use description: Users describe early changes in water, glycogen, and training feedback. These accounts do not establish an injection frequency or a predictable onset timeline.
Weeks 4–8: operating at full steady-state. Recovery between sessions improves. Training volume typically increases with it. The scale and the mirror start reflecting actual progress rather than just water and glycogen.
Weeks 8–16: tissue accrual is the primary variable. Diet and training compliance determine the outcome more than dose adjustment at this stage. This is where consistent execution matters more than pharmacology.
PCT timing is not established by this profile. It cannot be inferred from an ester half-life alone.
Source reference information
Community example · cadence/total inconsistency. Source context is nonmedical first-cycle use, not TRT. Its two cadence options are inconsistent with a single weekly total. References remain separate from quantities entered in a plan.
Starting: 500 mg/week total. Source lists E3D OR E3.5D alongside this weekly total. Wiki example weekly total for testosterone enanthate or cypionate. Population: Male first-cycle context in the community wiki. Route: intramuscular injection; formulation: Testosterone enanthate or cypionate. Source duration: Source example: 15 weeks. Not a TRT reference or medically validated safe starting dose. The source pairs 250 mg every 3 OR 3.5 days with 500 mg/week; only the 3.5-day option matches that weekly total. Source conflict: administration_example. Source: r/steroids: Your First Cycle.
Starting: 250 mg/administration. Every 3 days OR every 3.5 days. Per-administration version stated beside the weekly-total example. Population: Same wiki first-cycle example. Route: intramuscular injection; formulation: Testosterone enanthate or cypionate. Source duration: Source example: 15 weeks. E3D averages about 583.33 mg/week, not 500; E3.5D equals 500. Source alternatives are preserved, not averaged into one schedule. Source conflict: weekly_example. Source: r/steroids: Your First Cycle.
Adding an aromatase inhibitor to fix what is a dose or injection-spacing problem. Estradiol at week 3 of a cycle is still responding to rising blood levels and may not represent the stabilized level. Drawing labs and interpreting them against symptoms gives an actual picture. Reflexive AI use before labs means guessing.
Reading early scale movement as the actual result of the cycle. The first 3–4 weeks of water weight gain on testosterone often clears post-cycle, revealing the actual lean tissue underneath, which is usually more than expected.
Running the first cycle with multiple compounds. Testosterone plus two other drugs on a first cycle eliminates the ability to attribute any result, positive or negative, to a specific cause. That information is worth more than the marginal extra result from the second and third compounds.
Choosing a cycle length from a generic timeline. This profile does not establish a duration with a favorable risk-benefit balance.
Every other compound is evaluated relative to testosterone. Nandrolone and Primo provide more anabolic signal per unit of androgenic and estrogenic exposure. Trenbolone provides recomp effects and dramatic strength with no estrogen but at a significant quality-of-life cost. Masteron hardens the physique when body fat is low without adding estrogen or water. Equipoise adds work capacity and appetite stimulation with less estrogen than the equivalent testosterone dose.
None of these are replacements for testosterone. They are additions to or modifications of the base testosterone architecture, and the base still runs beneath all of them.